Program

Program

Scientific Co-Chairs: Darlene Dixon, DVM, PhD, DACVP, NIEHS/NTP, Research Triangle Park, NC; Kathryn E. Gropp, DVM, PhD, DACVP, Pfizer, Inc., Groton, CT; and Armando Irizarry, DVM, PhD, DACVP, Eli Lilly & Company, Indianapolis, IN

Continuing Education Chair: Emily Meseck, DVM, DACVP, DABT, Novartis Pharmaceuticals Corporation, East Hanover, NJ

Continuing Education Co-Chair: Kirstin F. Barnhart, DVM, PhD, DACVP, AbbVie, Inc., North Chicago, IL

The Basis and Relevance of Variation in Toxicologic Responses

Toxicologic responses elicited by chemical, pharmacological, or environmental agents can vary considerably among and within species and studies. Variation in toxicologic responses can confound results, complicate interpretation of data, interfere with reproducibility, and make extrapolation to humans problematic. Many factors can influence or be the source of significant variation in toxicologic responses. The 2016 STP symposium will focus on the basis and relevance of variation in toxicologic responses. Talks will describe key factors that impact the interpretation of nonclinical discovery and development studies. The symposium will kick off with “Real World Toxicology Outcomes: Impact of Species and Strain Selection on Drug Development Programs.” The following sessions will delve deep into topics that influence the accuracy of toxicology translatability to human health, including species and strain differences, animal model selection and disease predictability, genetics and epigenetics, hormones, age, drug metabolism, the microbiome, gene-environment interactions, formulations, study design (including special points to consider when designing developmental and reproductive toxicology studies), and much more. Prominent topics will include variables that influence the interpretation of clinical pathology parameters; the role of emerging technologies (genome-wide epigenetic and transcriptomic profiling) and modern data analyses (bioinformatics); and the impact of genotype-phenotype relationships in selecting the correct animal model, including non-human primates. This symposium will emphasize real-life examples to demonstrate how to identify the underlying causes of variability in nonclinical studies and to provide the background to place this variability into context for translation of animal data sets to human hazard identification and risk assessment.

This program 56-25618 is approved by the AAVSB RACE to offer a total of 20.00 CE Credits (20.00 max) being available to any one veterinarian: and/or 20.00 Veterinary Technician CE Credits (20.00 max). This RACE approval is for the subject matter categorie(s) of: Category One: Scientific using the delivery method(s) of: Seminar/Lecture. This approval is valid in jurisdictions which recognize AAVSB RACE; however, participants are responsible for ascertaining each board's CE requirements